VIA EDGAR
May 19, 2025
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attention: Tim Buchmiller
Re: Tango Therapeutics, Inc.
Acceleration Request for Registration Statement on Form S-3
File No. 333-287202
Dear Mr. Buchmiller,
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Tango Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to May 21, 2025, at 4:01 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling Marishka DeToy at (617) 570-1926.
If you have any questions regarding this request, please contact Marishka DeToy of Goodwin Procter LLP at (617) 570-1926.
| Sincerely, |
| TANGO THERAPEUTICS, INC. |
| /s/ Barbara Weber |
| Barbara Weber |
| Chief Executive Officer and President |
| cc: | Daniella Beckman, Tango Therapeutics, Inc. |
Douglas Barry, Tango Therapeutics, Inc.
Marishka DeToy, Esq., Goodwin Procter LLP